Cooper Companies: Business Model, SWOT Analysis, and Competitors 2026

The Cooper Companies, Inc. stands as a leading company in Healthcare. Generating $4.15 billion in annual revenue (growing 6.2% year-over-year) and carrying a market capitalization of $14.84 billion, the company has cemented its position as a foundational player in the global Medical Instruments & Supplies landscape. Under the leadership of its leadership team, The Cooper Companies, Inc. continues to execute on a multi-year strategic vision that balances growth investment with shareholder returns.

This in-depth analysis examines The Cooper Companies, Inc.'s business model, financial performance, competitive positioning, and SWOT analysis as of 2026. Whether you're evaluating The Cooper Companies, Inc. as an investment, benchmarking it against peers, or researching its strategy, this guide covers the key factors that define The Cooper Companies, Inc.'s position in the Medical Instruments & Supplies market today.

What You Will Learn

1. How The Cooper Companies, Inc. generates revenue across its key business segments and the unit economics behind each
2. A data-backed SWOT analysis covering The Cooper Companies, Inc.'s competitive strengths, operational weaknesses, market opportunities, and external threats
3. Who The Cooper Companies, Inc.'s main competitors are and how the company compares on key financial metrics
4. The Cooper Companies, Inc.'s key financial metrics: revenue, profit margins, market cap, free cash flow, and valuation multiples
5. The Cooper Companies, Inc.'s strategic direction and what to watch in 2026-2027

Key Takeaways

• Revenue: $4.15 billion annual revenue (TTM), +6.2% YoY
• Market Cap: $14.84 billion — one of the largest companies in the Healthcare sector
• Profitability: Gross margin 65.4%, operating margin 20.8%, net margin 9.7%
• Free Cash Flow: Data available in latest quarterly filing
• Return on Equity: 4.9% — reflects current investment phase
• Employees: 15,000 worldwide

Who Owns The Cooper Companies, Inc.?

The Cooper Companies, Inc. is publicly traded on the NASDAQ under the ticker symbol COO. As a public company, it is owned by millions of shareholders ranging from retail investors to major institutional holders.

The largest shareholders of The Cooper Companies, Inc. are typically major institutional investors including The Vanguard Group, BlackRock, and State Street Corporation — which collectively often hold 15-25% of publicly traded US companies. Insider ownership and the concentration of voting rights vary; investors should review the latest proxy statement filed with the SEC for precise ownership data.

The Cooper Companies, Inc. has approximately 195 million shares outstanding, with float shares of 196 million — the freely tradeable portion. The stock trades at $75.74 per share as of early 2026.

The Cooper Companies, Inc.'s Mission Statement

The Cooper Companies, Inc.'s strategic mission is aligned with its core business activities in the Medical Instruments & Supplies sector. The company's stated values and mission inform its capital allocation decisions, talent strategy, and long-term product roadmap. Mission statements for public companies are disclosed in annual reports and investor presentations — The Cooper Companies, Inc.'s most recent proxy statement and annual report are the authoritative sources for its current mission and values.

A company's mission statement matters because it signals strategic intent to employees, investors, and customers. For The Cooper Companies, Inc., the mission encompasses not just what the company does, but why it exists and how it creates value for stakeholders. Companies that maintain alignment between their stated mission and actual capital allocation decisions tend to build stronger brand trust and employee engagement over time.

In practice, The Cooper Companies, Inc.'s strategic priorities as communicated to investors in 2025-2026 center on revenue growth and market share expansion, profitability improvement, and sustainable returns of capital to shareholders. These operational priorities translate directly into the business model and investment thesis discussed in the following sections.

How Does The Cooper Companies, Inc. Make Money?

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group

The Cooper Companies, Inc.'s business model is built around delivering value to its customers in the Medical Instruments & Supplies segment of the Healthcare sector. The company generates revenue through its core product and service offerings, leveraging its market position, operational capabilities, and customer relationships to sustain competitive advantage. Like most companies in Medical Instruments & Supplies, The Cooper Companies, Inc.'s financial performance is influenced by industry-wide pricing dynamics, input costs, and the balance between volume growth and margin management.

Management's strategic priorities — as disclosed in investor communications — focus on sustainable revenue growth, disciplined capital allocation, and building long-term shareholder value. Investors should review The Cooper Companies, Inc.'s latest annual report (10-K or equivalent) and quarterly earnings releases for the most current financial disclosures and strategic updates.

The Cooper Companies, Inc. Business Model Canvas

The Business Model Canvas framework provides a structured view of how The Cooper Companies, Inc. creates, delivers, and captures value.

Key Partners: The Cooper Companies, Inc.'s key partners include suppliers, distributors, technology providers, and strategic alliances that enable its core operations. In the Medical Instruments & Supplies sector, these relationships provide supply chain resilience, expanded distribution, and access to complementary capabilities.

Key Activities: The Cooper Companies, Inc.'s most important activities center on product development and innovation, sales and marketing, supply chain management, customer service, and regulatory compliance. The company's ability to execute these activities at scale is a core competency.

Key Resources: The Cooper Companies, Inc.'s critical resources include its brand equity, intellectual property portfolio, customer relationships, human capital (15,000 employees), proprietary technology, and financial resources ($124.90M in cash).

Value Propositions: The Cooper Companies, Inc. delivers value to customers through product quality, brand trust, convenience, innovation, and price competitiveness. The specific value proposition varies by customer segment but consistently addresses core needs in the Medical Instruments & Supplies market.

Customer Relationships: The Cooper Companies, Inc. maintains customer relationships through multiple channels including direct sales teams, digital platforms, customer service centers, and loyalty/membership programs. Customer retention is a key operational priority.

Channels: The Cooper Companies, Inc. reaches customers through its own direct channels (stores, website, apps), third-party retailers and distributors, and partner networks. The mix of direct vs. indirect channels affects margin structure and customer data ownership.

Customer Segments: The Cooper Companies, Inc. serves multiple distinct customer segments, which may include consumers, small and medium businesses, enterprise clients, and government entities — depending on its product portfolio and market positioning.

Cost Structure: The Cooper Companies, Inc.'s major costs include cost of goods sold (34.6% of revenue), research & development, sales & marketing, general & administrative expenses, and capital expenditures. Total operating costs represent 79.2% of revenue.

Revenue Streams: The Cooper Companies, Inc. generates revenue through its core product and service offerings.

The Cooper Companies, Inc. Competitors

The Cooper Companies, Inc. competes against Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Pfizer (PFE), AbbVie (ABBV), Eli Lilly (LLY) and others in the Medical Instruments & Supplies segment of the Healthcare sector.

The Cooper Companies, Inc. SWOT Analysis

A SWOT analysis examines The Cooper Companies, Inc.'s internal strengths and weaknesses alongside external opportunities and threats.

Strengths

• Strong Margins: The Cooper Companies, Inc.'s gross margin of 65.4% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 20.8% demonstrates disciplined cost management even at scale.

Weaknesses

• Competitive Scale Pressure: In the Medical Instruments & Supplies sector, larger competitors with greater economies of scale can exert pricing pressure and outspend The Cooper Companies, Inc. on marketing, R&D, and distribution — limiting the company's ability to defend market share in a price-sensitive environment.
• Market Concentration Risk: Revenue concentration in core markets or customer segments creates vulnerability to localized downturns, regulatory changes, or shifts in customer preferences. Diversification remains an ongoing strategic challenge.

Opportunities

• Total Addressable Market: The Cooper Companies, Inc. operates in the Medical Instruments & Supplies segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environment translate to meaningful revenue upside, particularly as the company expands its product portfolio and geographic reach.
• International Expansion: Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for The Cooper Companies, Inc.'s products and services.
• Earnings Momentum: Earnings growth of 26.9% YoY demonstrates The Cooper Companies, Inc.'s ability to convert revenue growth into shareholder value. Analysts project continued earnings expansion driven by operating leverage as fixed costs are amortized across a growing revenue base.
• Strategic Acquisitions: With $124.90M in cash and strong free cash flow generation, The Cooper Companies, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Threats

• Macroeconomic Sensitivity: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. The Cooper Companies, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scenario could meaningfully impact demand.
• Regulatory and Geopolitical Risk: Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on The Cooper Companies, Inc.'s business model across key markets.
• Talent Competition: Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly critical in an era of AI-driven competition.

Conclusion

The Cooper Companies, Inc. enters 2026 as a leading company in Healthcare, backed by $4.15 billion in annual revenue and a 9.7% net profit margin. The company's 65.4% gross margins and N/A in free cash flow provide the financial foundation to fund growth initiatives while returning capital to shareholders.

The primary opportunities ahead lie in expanding market share, operational efficiency improvements, and selective geographic expansion. The key risks to monitor include competitive pressure from established peers and new entrants, macroeconomic headwinds, and regulatory developments in The Cooper Companies, Inc.'s core markets.

For investors, The Cooper Companies, Inc.'s 40.5x trailing P/E and 15.1x forward P/E reflect the market's expectations for stable earnings. Analysts and investors should watch quarterly earnings releases, management commentary on comparable sales growth, margin trends, and capital allocation for signals of how the investment thesis is progressing.

Frequently Asked Questions

1. What does The Cooper Companies, Inc. do?

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges,

2. How much revenue does The Cooper Companies, Inc. make?

The Cooper Companies, Inc. generated $4.15 billion in annual revenue (TTM), with 6.2% year-over-year growth.

3. What is The Cooper Companies, Inc.'s market cap?

The Cooper Companies, Inc.'s market capitalization is approximately $14.84 billion as of early 2026.

4. Is The Cooper Companies, Inc. profitable?

Yes. The Cooper Companies, Inc. has a net profit margin of 9.7% and a return on equity of 4.9%.

5. Who are The Cooper Companies, Inc.'s competitors?

The Cooper Companies, Inc. competes in the Medical Instruments & Supplies sector against companies including Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Pfizer (PFE).

6. Does The Cooper Companies, Inc. pay dividends?

The Cooper Companies, Inc. does not currently pay a dividend, choosing to reinvest earnings into growth initiatives.

7. What is The Cooper Companies, Inc.'s stock ticker?

The Cooper Companies, Inc. trades on the NASDAQ under the ticker symbol COO.

8. What is The Cooper Companies, Inc.'s P/E ratio?

The Cooper Companies, Inc.'s trailing P/E ratio is 40.5x and forward P/E is 15.1x, suggesting the market anticipates continued earnings growth.

9. How many employees does The Cooper Companies, Inc. have?

The Cooper Companies, Inc. employs approximately 15,000 people worldwide as of the most recent disclosure.

10. What is The Cooper Companies, Inc.'s competitive advantage?

The Cooper Companies, Inc.'s competitive advantages include its established brand, scale in Medical Instruments & Supplies, and track record of execution in the Healthcare sector.